Vidofludimus misses primary endpoint in RA trial

4SC AG has announced that a Phase 2b trial of its small molecule inhibitor of pro-inflammatory cytokines, vidofludimus, failed to meet its primary endpoint in a Phase 2b trial of patients with rheumatoid arthritis.